Dr. Liu earned a Ph.D. in immunology from Harvard University, a master’s degree in Medical Sciences from Harvard Medical School, a bachelor’s degree in Biochemistry from Cornell University and an EMBA degree from Cheung Kong Graduate School of Business. Around six years before she joined in Kaiwu Capital, she was active in biomedical investment. Once served as the managing director of China Renaissance Capital Investment, Dr. Liu played a leading role in investing five biomedical projects and one clean technology project, among which Celgen Biopharma was listed in 2011. As an angel investor, she jointly established Shenogen Pharma Group which is dedicated to researching and developing novel medicine for tumor stem cells. From 2000 to 2004, Liu Qianye served as a senior manager in 3721 Technology Company Ltd. until it was acquired by Yahoo. In her early age, Dr. Liu worked in McKinsey & Company, possessing rich experience in management consulting.